Zydus Lifesciences share price

Balanced risk
  • 28%Low risk
  • 28%Moderate risk
  • 28%Balanced risk
  • 28%High risk
  • 28%Extreme risk
  • 913.80(1.20%)
    May 19, 2025 13:14:34 PM IST
    • NSE
    • BSE
  • Vol : 611.03K (NSE + BSE)
    Last 20 day avg : 1.20 M

Zydus Lifesciences is trading 1.20% upper at Rs 913.80 as compared to its last closing price. Zydus Lifesciences has been trading in the price range of 919.65 & 902.90. Zydus Lifesciences has given -7.10% in this year & 2.74% in the last 5 days. Zydus Lifesciences has TTM P/E ratio 21.59 as compared to the sector P/E of 24.50.There are 27 analysts who have initiated coverage on Zydus Lifesciences. There are 3 analysts who have given it a strong buy rating & 9 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 1,023.50 Crores in its last quarter.Listed peers of Zydus Lifesciences include Dr Reddys Laboratories (-0.86%), Lupin (-0.91%), Zydus Lifesciences (1.20%).The Mutual Fund holding in Zydus Lifesciences was at 6.36% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Zydus Lifesciences was at 7.31% in 31 Mar 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Key Metrics

Updated on May 19, 2025, 07:44 AM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.33
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    4.58
    Lower than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    20.05
    Lower than historical values
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.55
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.04
    Higher than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
902.90
Highest
919.65
52 week range
Lowest
797.05
Highest
1,323.90
Zydus Lifesciences Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in December quarter by 16.96% from Rs 5269.10 crore to Rs 4505.20 crore, year-on-year
    • financial-insightsThe company has grown its December quarter profit by 29.62% from Rs 789.60 crore to Rs 1023.50 crore, year-on-year
    • financial-insightsThe debt to equity of the company is higher than the industry median
Zydus Lifesciences Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 912.78
  • R2
  • 937.87
  • R3
  • 966.33
Pivot884.32
  • S1
  • 859.23
  • S2
  • 830.77
  • S3
  • 805.68
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Zydus Lifesciences Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Dr Reddys Laboratories
Moderately Bullish
1,219.95-0.861,01,947.3518.113.050.652.34
Lupin
Bearish
2,049.55-0.9193,585.8428.855.490.3911.80
Zydus Lifesciences
Neutral
913.801.2091,873.4723.814.580.330.13
Abbott India
Bullish
30,550.00-0.0465,112.1445.9115.341.553.73
Alkem Laboratories
Moderately Bullish
5,386.053.1664,398.3134.716.050.802.22
Zydus Lifesciences Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Zydus Lifesciences is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPromoter(s) holds a high stake in the company at 74.99%
    • InsightsPromoter(s) have increased the stake in the company in last 12 months
    • InsightsFIIs are invested in this company
    • InsightsFIIs holding has decreased by 0.22 percentage points from previous quarter
    • InsightsMutual Funds holding has increased by 0.04 percentage points from previous quarter
    Mutual Fund Ownership
    View all
    ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
    NA
    • Amount Invested (Cr.) 205.79
    • % of AUM 3.89
    ICICI Prudential Nifty Pharma Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 2.39
    • % of AUM 2.87
    Kotak Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 10.22
    • % of AUM 2.47
    Nippon India Nifty Alpha Low Volatility 30 Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 31.54
    • % of AUM 2.34
    ICICI Prudential MNC Fund Regular Growth
    NA
    • Amount Invested (Cr.) 37.57
    • % of AUM 2.34
    Zydus Lifesciences Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-05-20Audited Results & Final Dividend
    2025-02-05Quarterly Results
    2024-11-12Quarterly Results
    2024-08-09Quarterly Results
    2024-05-17Audited Results & Final Dividend
    About the company Zydus Lifesciences
    • IndustryBiotechnology & Drugs
    • ISININE010B01027
    • BSE Code532321
    • NSE CodeZYDUSLIFE
    Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
    • Management Info
    • Nitin ParekhChief Financial Officer
    • Dhaval SoniCompany Secretary, Compliance Officer
    • Sharvil PatelManaging Director, Executive Director
    • Ganesh NayakExecutive Director
    Zydus Lifesciences Share Price FAQs

    Zydus Lifesciences is trading at 913.80 as on Mon May 19 2025 07:44:34. This is 1.20% upper as compared to its previous closing price of 903.00.

    The market capitalization of Zydus Lifesciences is 91873.47 Cr as on Mon May 19 2025 07:44:34.

    The average broker rating on Zydus Lifesciences is Hold. The breakup of analyst rating is given below -

    • 3 analysts have given a strong buy rating
    • 9 analysts have given a buy rating
    • 10 analysts have given a hold rating
    • 3 analysts have given a sell rating
    • 2 analysts have given a strong sell rating

    The 52 wk high for Zydus Lifesciences is 1323.90 whereas the 52 wk low is 797.05

    Zydus Lifesciences can be analyzed on the following key metrics -

    • TTM P/E: 21.59
    • Sector P/E: 24.50
    • Dividend Yield: 0.33%
    • D/E ratio: -

    Zydus Lifesciences reported a net profit of 3859.50 Cr in 2024.

    The Mutual Fund Shareholding was 6.36% at the end of 31 Mar 2025.